|
|
|
|
|
|
|
EXPERT-LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
|
The Efficacy of PARP Inhibition in BRCA1- versus BRCA2-Altered mCRPC - Journal Club
|
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen discuss a publication entitled “Differential Activity of PARP Inhibitors in BRCA1-Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.” Olaparib and Rucaparib are US Food and Drug Administration-approved for patients with mCRPC harboring BRCA1/2 mutations.
|
|
|
|
|
|
|
|
|
| Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes-Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen focus this discussion on the article published in The Lancet titled "Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound)."
|
|
|
|
|
|
|
|
|
|
|
| Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone."
|
|
|
|
|
|
| Efficacy and Safety of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Defects (GALAHAD) - Journal Club
|
| Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen highlight the multicentre, open-label, phase 2 GALAHAD trial. In this trial, the authors evaluated the anti-tumour activity and safety of the PARP inhibitor, niraparib in patients with metastatic castration-resistant prostate cancers and DNA repair gene defects (DRDs) who progressed on previous treatment with an androgen signaling inhibitor and a taxane.
|
|
|
|
|
|
|
|
|
|
|
|
